Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990607 | 0.86 | TSHR (0.31) | TSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL3224166 | 0.83 | TSHR (0.39) | TSHRALDH1A1TDP1CA1CA12 | |
| SCHEMBL27695605 | 0.82 | GABRR1 (0.41) | — | |
| SCHEMBL3255350 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1TDP1ZDHHC20ZDHHC2 | |
| SCHEMBL14413490 | 0.82 | ZDHHC20 (0.30) | ZDHHC20ZDHHC2 | |
| SCHEMBL24363224 | 0.81 | GABBR2 (0.31) | — | |
| SCHEMBL28649883 | 0.81 | ZDHHC20 (0.31) | TSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL27695554 | 0.80 | — | — | |
| SCHEMBL27695859 | 0.80 | ZDHHC20 (0.30) | ZDHHC20ZDHHC2 | |
| SCHEMBL3273294 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2020-09-03 | — | — | US | disclosed |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-20120184013-A1 | Inhibitors of BMX non-receptor tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | TSHR 4752/4885ALDH1A1 2792/4885TDP1 3544/4885 |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | TSHR 2700/4885ALDH1A1 4263/4885TDP1 896/4885 |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | TSHR 2001/4885ALDH1A1 3889/4885TDP1 958/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | TSHR 4752/4885ALDH1A1 2792/4885TDP1 3544/4885 |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | TSHR 2102/4885ALDH1A1 4521/4885TDP1 348/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | TSHR 2001/4885ALDH1A1 3889/4885TDP1 958/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | TSHR 4752/4885ALDH1A1 2792/4885TDP1 3544/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | TSHR 4752/4885ALDH1A1 2792/4885TDP1 3544/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | TSHR 4752/4885ALDH1A1 2792/4885TDP1 3544/4885 |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 2734/4885ALDH1A1 4019/4885TDP1 365/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | TSHR 2102/4885ALDH1A1 4521/4885TDP1 348/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | TSHR 2102/4885ALDH1A1 4521/4885TDP1 348/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TSHR 3200/4885ALDH1A1 4117/4885TDP1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.